FDA Guidance Addresses Wave Of Impurities In Popular Drugs

By Dave Simpson (September 1, 2020, 9:46 PM EDT) -- The U.S. Food and Drug Administration released guidance Tuesday to help drug companies detect and prevent unacceptable levels of nitrosamine impurities, which have been linked to cancer and triggered recalls of the blood pressure drug valsartan, diabetes drug metformin and heartburn drug ranitidine.

The most common nitrosamine impurity, n-nitrosodimethylamine, or NDMA, is classified by the FDA as a probable human carcinogen, and its discovery in the heartburn medication commonly known as Zantac led to the recall of that drug earlier this year.

"This guidance recommends steps including a comprehensive risk assessment strategy and other actions that manufacturers can take to reduce...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!